Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2012 Apr;33(4):173-80. doi: 10.1016/j.tips.2012.02.001. Epub 2012 Mar 10.

The Valley of Death in anticancer drug development: a reassessment.

Author information

1
Department of Medicine, Duke University Health System, Duke Box # 2638, Research Drive, Durham, NC 27710, USA. adams041@mc.duke.edu

Abstract

The past decade has seen an explosion in our understanding of cancer biology and with it many new potential disease targets. Nonetheless, our ability to translate these advances into therapies is poor, with a failure rate approaching 90%. Much discussion has been devoted to this so-called 'Valley of Death' in anticancer drug development, but the problem persists. Could we have overlooked some straightforward explanations to this highly complex problem? Important aspects of tumor physiology, drug pharmacokinetics, preclinical models, drug delivery, and clinical translation are not often emphasized, but could be crucial. This perspective summarizes current views on the problem and suggests feasible alternatives.

PMID:
22410081
PMCID:
PMC3324971
DOI:
10.1016/j.tips.2012.02.001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center